Collegium Pharmaceutical, Inc.
COLL
$36.05
$1.253.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 780.57M | 757.07M | 707.01M | 664.28M | 631.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 780.57M | 757.07M | 707.01M | 664.28M | 631.45M |
| Cost of Revenue | 89.99M | 89.55M | 88.30M | 86.07M | 83.53M |
| Gross Profit | 690.58M | 667.51M | 618.71M | 578.22M | 547.92M |
| SG&A Expenses | 278.28M | 273.32M | 249.84M | 217.42M | 182.98M |
| Depreciation & Amortization | 221.89M | 221.89M | 207.22M | 186.26M | 165.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 590.16M | 584.77M | 545.36M | 489.75M | 431.82M |
| Operating Income | 190.40M | 172.30M | 161.65M | 174.53M | 199.63M |
| Income Before Tax | 92.62M | 80.85M | 53.00M | 65.07M | 98.57M |
| Income Tax Expenses | 29.75M | 22.41M | 16.73M | 21.17M | 29.38M |
| Earnings from Continuing Operations | 62.87 | 58.44 | 36.27 | 43.89 | 69.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.87M | 58.44M | 36.27M | 43.89M | 69.19M |
| EBIT | 190.40M | 172.30M | 161.65M | 174.53M | 199.63M |
| EBITDA | 416.48M | 398.49M | 373.08M | 364.82M | 368.79M |
| EPS Basic | 1.99 | 1.84 | 1.13 | 1.36 | 2.14 |
| Normalized Basic EPS | 2.36 | 1.89 | 1.73 | 2.11 | 2.70 |
| EPS Diluted | 1.71 | 1.60 | 1.03 | 1.21 | 1.85 |
| Normalized Diluted EPS | 1.90 | 1.54 | 1.41 | 1.71 | 2.15 |
| Average Basic Shares Outstanding | 126.83M | 127.25M | 127.94M | 128.56M | 129.10M |
| Average Diluted Shares Outstanding | 151.43M | 151.47M | 152.19M | 153.50M | 162.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |